CLINICAL_TRIALS
trial_result
· 2025-12-17
Clinical Trial Update: Extension Study of Participants From SPG302-ALS-001 [Phase 2]
Summary
An extension study of SPG302-ALS-001 in participants with amyotrophic lateral sclerosis has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Spinogenix | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Status: TERMINATED